Cancer and pharmaceutical companies. About Vir Biotechnology, Inc. In other recent news, Kairos Pharma has signed a term sheet to acquire two clinical-stage oncology assets from Celyn Therapeutics. Learn about the top 20 companies leading the market in 2025. astellas. 15 hours ago · US pharma major Merck (NYSE: MRK) has reported a Phase III success for Welireg (belzutifan) plus Keytruda (pembrolizumab) as adjuvant therapy for clear cell renal cell carcinoma after surgery, cutting the risk of recurrence or death by 28% versus Keytruda alone. Aug 9, 2025 · Cancer therapeutic companies like Bristol-Myers Squibb and Merck have pioneered checkpoint inhibitors that enhance immune response against tumors. At first glance, the list of cancer drug makers predicted to head the field by 2024 may not look so different from the list of top-selling cancer drug makers in 2017. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Feb 23, 2026 · ImmunityBio shares surge on 700% revenue growth driven by sales of Anktiva, the company's approved drug for bladder cancer. Nov 13, 2025 · In summary, while Roche, Bristol-Myers Squibb (with Celgene), and other legacy leaders remain influential, the cancer drug market in 2024 is far more competitive and fragmented than in the past. com. ADCs offer high specificity and reduced Myriad Genetics hereditary cancer, prenatal, oncology and mental health genetic testing insights can help detect, treat and prevent disease. Feb 23, 2026 · ORIC Pharmaceuticals (NasdaqGS:ORIC) reports progress in its cancer therapy pipeline, with lead drug candidates entering Phase 1b clinical trials. Vir Biotechnology, Inc. The company announces new collaborations with Pfizer, Bayer, and Johnson & Johnson, aimed at advancing therapies that target resistance mechanisms in cancer treatment. 6 days ago · Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors. Explore insights on top cancer drug manufacturing companies, including TherDose Pharma and Chi-Med, driving advancements in oncology solutions. Explore how 23 top oncology drugs companies are transforming cancer care, driving innovation, and redefining competitiveness in the global market. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. These breakthrough treatments have shown impressive results in various cancer types, including melanoma and lung cancer. Stay updated with the latest news and stories from around the world on Google News. Sep 3, 2025 · Explore the future of oncology with ADCs, cell therapies, and radioligand therapies. . It also Feb 23, 2026 · Learn more at www. 31 minutes ago · The market for Antibody-drug Conjugates (ADCs) in oncology presents significant opportunities with over 200 companies and 220 drugs in development globally. Get started today. In one announcement, Vir said it has partnered with Astellas Pharma on the therapy, a “masked” T cell engager known as VIR-5500. Strong partnerships and clinical trials position Anktiva as key to its Feb 22, 2026 · Merck: This Cancer‑Drug Powerhouse Could Be a Core Dividend Holding for Decades The company might bend, but it won't break. These developments are drawing increased investor attention as they represent 15 hours ago · NATCO Pharma launches generic Pomalidomide capsules for blood cancer treatment in the US with Breckenridge Pharmaceutical. 1 day ago · The company is based in Los Angeles, California. Feb 24, 2026 · Dive Brief: Shares for Vir Biotechnology climbed by nearly 30% Tuesday after the company reported positive early data as well as a partnership involving an experimental drug it’s developing for prostate cancer. 16 hours ago · DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insights 2026” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. BioNTech develops mRNA cancer immunotherapies, next-generation immunomodulators and targeted therapies in oncology, and vaccines against infectious diseases. wrn ifz kdx lgt rda gbj tnt nge xae cde eoj rlm fkl afs lkt